• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Pseudoaccommodative IOL achieves excellent near visual acuity

Article

Paris—Visual acuity results from an international multicenter study demonstrate the AcrySof ReSTOR (Alcon Laboratories) apodized diffractive pseudoaccommodative IOL offers excellent near visual acuity that is independent of pupil size and achieved without compromising distance vision, said Thomas Kohnen, MD.

"This pseudoaccommodative IOL preserves the biomaterial benefits of the AcrySof IOL but incorporates the advantages of a diffractive structure design over 3.6 mm of the anterior surface to optimize for pupil independent vision. Focus visual acuity testing results in this study demonstrate both models of the AcrySof ReSTOR demonstrate a broad range of functionality, including functional intermediate vision and excellent near vision at all pupil sizes," Dr. Kohnen said.

The trial was conducted in the United States and countries in the European Union and was a nonmasked, nonrandomized, parallel study of patients undergoing bilateral implantation with the three-piece AcrySof ReSTOR model SA60D3 (n = 440), the newer one-piece AcrySof ReSTOR model MA60D3 (n = 126), or the control monofocal AcrySof model MA60BM (n = 194). All one-piece ReSTOR and monofocal AcrySof IOLs were implanted in U.S. centers.

Extensive visual acuity testing was performed, including standard distance and near testing as well as at intermediate distances of 50, 60, and 70 cm. Both photopic and mesopic lighting conditions were used and testing was performed with best and standard reading distances.

The visual acuity results achieved in the ReSTOR groups were favorable after single eye implantation and improved further with bilateral implantation.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.